Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Children With ADHD Who do Not Fully Respond to Stimulants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. English or Spanish speaking parent/guardian. Parent/guardian and child must be able to understand the protocol.~2. Primary diagnosis of ADHD despite treatment with a stimulant by the primary care treatment provider.~3. Non-responder or partial responder to stimulant treatment. ADHD symptoms and clinical impairment despite treatment with stimulant (including OROS-MPH \[Concerta\] or mixed salts amphetamine \[Adderall\]).~4. IQ of greater than 70.~5. The subject must be in school.~6. The family must be able to attend weekly visits.~Exclusion Criteria:~1. Unable to understand protocol or follow study procedures.~2. Subject doing well on stimulants.~3. Subjects showing lack of response or minimal response to stimulants due to non-compliance with taking medication or taking suboptimal doses.~4. Autism, Psychosis, Bipolar Disorder, Drug Abuse, significant suicidality, or any other psychiatric disorder (such as MDD, Anxiety Disorders, Eating Disorders) in addition to ADHD that will require treatment with additional medication or therapy.~5. The subject is using or abusing recreational drugs or has a positive urine toxicology screen (except for stimulants).~6. The subject has a history of physical, sexual, or emotional abuse that resulted in a clinically significant impact on clinical presentation, potentially driving some of the symptoms of ADHD.~7. Females who are pregnant or breast-feeding or who have a positive urine pregnancy test.~8. Sexually active females and males who do not agree to use adequate birth control.~9. Abnormal cardiac function.~10. Subject is taking prohibited concomitant medication during phase 1 or phase 2 of the trial.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- aripiprazole (Type: ACTIVE_COMPARATOR): This treatment arm (also called the combination arm) consists of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus augmentation with aripiprazole. Aripiprazole pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis. Dosing will start at 2.5 mg and will be titrated up to 5 mg by week 1, and up to 10 mg by week 2 and for the remainder of the trial.
- Sugar pill (Type: PLACEBO_COMPARATOR): This treatment arm (also called the simple treatment arm) will consist of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus a placebo matching aripiprazole. Placebo pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).